Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.

Travers M, Brown SM, Dunworth M, Holbert CE, Wiehagen KR, Bachman KE, Foley JR, Stone ML, Baylin SB, Casero RA Jr, Zahnow CA.

Cancer Res. 2019 Jul 1;79(13):3445-3454. doi: 10.1158/0008-5472.CAN-18-4018. Epub 2019 May 14.

PMID:
31088836
2.

Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.

Kong X, Chen J, Xie W, Brown SM, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann RL, Tao Y, Chiu Yen RW, Topper MJ, Zahnow CA, Easwaran H, Rothbart SB, Xia L, Baylin SB.

Cancer Cell. 2019 Apr 15;35(4):633-648.e7. doi: 10.1016/j.ccell.2019.03.003. Epub 2019 Apr 4.

PMID:
30956060
3.

Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis.

Tao Y, Kang B, Petkovich DA, Bhandari YR, In J, Stein-O'Brien G, Kong X, Xie W, Zachos N, Maegawa S, Vaidya H, Brown S, Chiu Yen RW, Shao X, Thakor J, Lu Z, Cai Y, Zhang Y, Mallona I, Peinado MA, Zahnow CA, Ahuja N, Fertig E, Issa JP, Baylin SB, Easwaran H.

Cancer Cell. 2019 Feb 11;35(2):315-328.e6. doi: 10.1016/j.ccell.2019.01.005.

PMID:
30753828
4.

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ.

Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25.

PMID:
30454645
5.

Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic.

Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8583-E8584. doi: 10.1073/pnas.1811015115. Epub 2018 Sep 4. No abstract available.

6.

Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma.

De Carvalho Fischer C, Hu Y, Morreale M, Lin WY, Wali A, Thakar M, Karunasena E, Sen R, Cai Y, Murphy L, Zahnow CA, Keer H, Thakar M, Ahuja N.

Oncotarget. 2018 Apr 10;9(27):19379-19395. doi: 10.18632/oncotarget.25056. eCollection 2018 Apr 10.

7.

DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk.

Xie W, Kagiampakis I, Pan L, Zhang YW, Murphy L, Tao Y, Kong X, Kang B, Xia L, Carvalho FLF, Sen S, Chiu Yen RW, Zahnow CA, Ahuja N, Baylin SB, Easwaran H.

Cancer Cell. 2018 Feb 12;33(2):309-321.e5. doi: 10.1016/j.ccell.2018.01.008.

8.

Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248. doi: 10.1073/pnas.1718197115. Epub 2018 Jan 24.

9.

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.

Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM.

Nat Commun. 2018 Jan 16;9(1):248. doi: 10.1038/s41467-017-02630-w.

10.

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990. doi: 10.1073/pnas.1712514114. Epub 2017 Dec 4.

11.

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.

Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, Strick R, Velculescu VE, Baylin SB.

Cell. 2017 Nov 30;171(6):1284-1300.e21. doi: 10.1016/j.cell.2017.10.022.

12.

Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations.

Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O'Hagan HM, Murphy L, Zahnow CA, Gabrielson E, Velculescu VE, Easwaran HP, Baylin SB.

Cancer Cell. 2017 Sep 11;32(3):360-376.e6. doi: 10.1016/j.ccell.2017.08.006.

13.

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes.

Xia L, Huang W, Bellani M, Seidman MM, Wu K, Fan D, Nie Y, Cai Y, Zhang YW, Yu LR, Li H, Zahnow CA, Xie W, Chiu Yen RW, Rassool FV, Baylin SB.

Cancer Cell. 2017 May 8;31(5):653-668.e7. doi: 10.1016/j.ccell.2017.04.005.

14.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2017 Apr 6;169(2):361. doi: 10.1016/j.cell.2017.03.036. No abstract available.

15.

Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.

Merino VF, Cho S, Liang X, Park S, Jin K, Chen Q, Pan D, Zahnow CA, Rein AR, Sukumar S.

Mol Oncol. 2017 May;11(5):552-566. doi: 10.1002/1878-0261.12053. Epub 2017 Apr 6.

16.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

17.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

18.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2016 Feb 25;164(5):1073. doi: 10.1016/j.cell.2015.10.020. Epub 2016 Feb 25. No abstract available.

19.

Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.

Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB, Casero RA Jr.

Adv Cancer Res. 2016;130:55-111. doi: 10.1016/bs.acr.2016.01.007. Epub 2016 Mar 2. Review.

PMID:
27037751
20.

Combining Epigenetic and Immunotherapy to Combat Cancer.

Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB.

Cancer Res. 2016 Apr 1;76(7):1683-9. doi: 10.1158/0008-5472.CAN-15-2125. Epub 2016 Mar 17. Review.

21.

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.

Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A.

Oncotarget. 2015 Oct 6;6(30):29143-60. doi: 10.18632/oncotarget.5020.

22.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R.

Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011. Erratum in: Cell. 2016 Feb 25;164(5):1073. Buhu, Sadna [corrected to Budhu, Sadna]; Mergoub, Taha [corrected to Merghoub, Taha]. Cell. 2017 Apr 6;169(2):361.

23.

A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis.

Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, Pan D.

Genes Dev. 2014 Mar 1;28(5):432-7. doi: 10.1101/gad.233676.113.

24.

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N.

Oncotarget. 2014 Feb 15;5(3):587-98.

25.

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

26.

Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells.

Di Cello F, Flowers VL, Li H, Vecchio-Pagán B, Gordon B, Harbom K, Shin J, Beaty R, Wang W, Brayton C, Baylin SB, Zahnow CA.

Mol Cancer. 2013 Aug 6;12:90. doi: 10.1186/1476-4598-12-90.

27.

Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer.

Di Cello F, Cope L, Li H, Jeschke J, Wang W, Baylin SB, Zahnow CA.

PLoS One. 2013 Jul 3;8(7):e68630. doi: 10.1371/journal.pone.0068630. Print 2013.

28.

The future of epigenetic therapy in solid tumours--lessons from the past.

Azad N, Zahnow CA, Rudin CM, Baylin SB.

Nat Rev Clin Oncol. 2013 May;10(5):256-66. doi: 10.1038/nrclinonc.2013.42. Epub 2013 Apr 2. Review.

29.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA.

Cancer Cell. 2012 Mar 20;21(3):430-46. doi: 10.1016/j.ccr.2011.12.029.

30.

LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis.

Li H, Baldwin BR, Zahnow CA.

Mol Cancer. 2011 Aug 19;10:100. doi: 10.1186/1476-4598-10-100.

31.

Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, Ambinder RF.

Blood. 2011 Jun 9;117(23):6297-303. doi: 10.1182/blood-2011-01-332379. Epub 2011 Mar 29.

32.

Epigenetic networks and miRNAs in stem cells and cancer.

Zahnow CA, Baylin SB.

Mol Cell. 2010 Sep 10;39(5):661-3. doi: 10.1016/j.molcel.2010.08.036.

33.

CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Zahnow CA.

Expert Rev Mol Med. 2009 Apr 8;11:e12. doi: 10.1017/S1462399409001033. Review.

34.

Ha-Ras transformation of MCF10A cells leads to repression of Singleminded-2s through NOTCH and C/EBPbeta.

Gustafson TL, Wellberg E, Laffin B, Schilling L, Metz RP, Zahnow CA, Porter WW.

Oncogene. 2009 Mar 26;28(12):1561-8. doi: 10.1038/onc.2008.497. Epub 2009 Jan 26.

35.

A histological survey of green fluorescent protein expression in 'green' mice: implications for stem cell research.

Biankin SA, Collector MI, Biankin AV, Brown LJ, Kleeberger W, Devereux WL, Zahnow CA, Baylin SB, Watkins DN, Sharkis SJ, Leach SD.

Pathology. 2007 Apr;39(2):247-51.

PMID:
17454756
36.

ErbB receptors and their ligands in the breast.

Zahnow CA.

Expert Rev Mol Med. 2006 Sep 20;8(23):1-21. Review.

PMID:
16984691
37.

Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.

Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB.

Cancer Cell. 2004 Oct;6(4):387-98.

39.

A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME.

Cell. 2003 Aug 8;114(3):323-34.

40.

CCAAT/enhancer binding proteins in normal mammary development and breast cancer.

Zahnow CA.

Breast Cancer Res. 2002;4(3):113-21. Epub 2002 Apr 19. Review.

41.

A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation.

Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM.

Cancer Res. 2001 Jan 1;61(1):261-9.

42.

Glucocorticoid hormones downregulate histidine decarboxylase mRNA and enzyme activity in rat lung.

Zahnow CA, Panula P, Yamatodani A, Millhorn DE.

Am J Physiol. 1998 Aug;275(2):L407-13. doi: 10.1152/ajplung.1998.275.2.L407.

PMID:
9700103
43.

Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.

Zahnow CA, Younes P, Laucirica R, Rosen JM.

J Natl Cancer Inst. 1997 Dec 17;89(24):1887-91.

PMID:
9414177
44.
45.

Localization of histidine decarboxylase mRNA in rat brain.

Bayliss DA, Wang YM, Zahnow CA, Joseph DR, Millhorn DE.

Mol Cell Neurosci. 1990 Aug;1(1):3-9.

PMID:
19912749
46.

Characterization and expression of the complementary DNA encoding rat histidine decarboxylase.

Joseph DR, Sullivan PM, Wang YM, Kozak C, Fenstermacher DA, Behrendsen ME, Zahnow CA.

Proc Natl Acad Sci U S A. 1990 Jan;87(2):733-7. Erratum in: Proc Natl Acad Sci U S A 1990 Sep;87(18):7346.

47.

Primary structure of an analog of crustacean pigment-dispersing hormone from the lubber grasshopper Romalea microptera.

Rao KR, Mohrherr CJ, Riehm JP, Zahnow CA, Norton S, Johnson L, Tarr GE.

J Biol Chem. 1987 Feb 25;262(6):2672-5.

48.

C-terminal deletion analogs of a crustacean pigment-dispersing hormone.

Riehm JP, Rao KR, Semmes OJ, Jorenby WH, Hintz MF, Zahnow CA.

Peptides. 1985 Nov-Dec;6(6):1051-6.

PMID:
3841733
49.

Characterization of a pigment-dispersing hormone in eyestalks of the fiddler crab Uca pugilator.

Rao KR, Riehm JP, Zahnow CA, Kleinholz LH, Tarr GE, Johnson L, Norton S, Landau M, Semmes OJ, Sattelberg RM, Jorenby WH, Hintz MF.

Proc Natl Acad Sci U S A. 1985 Aug;82(16):5319-22.

Supplemental Content

Loading ...
Support Center